Clinical trial
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT00346918 · University of Zurich, Other · Completed
Key facts
| NCT number | NCT00346918 |
|---|---|
| Title | Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
| Official title | Sirolimus (Rapamune®) for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD): a Randomized Controlled Study. |
| Lead sponsor | University of Zurich, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
| Intervention type | Drug, Other |
| Interventions | Sirolimus, Standard |
| Enrollment | 100 |
| Start date | Jun 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Jun 30, 2006 |
| Last update posted | Feb 27, 2014 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: